Reducing Cesarean Childbirth Rates Using the Hem-Avert Perianal Stabilizer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to evaluate an FDA approved device called the HEM-AVERT® Perianal Stabilizer and the efficacy in reducing the C-section rate and/or reducing the second stage of labor times.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Hem-Avert® Perianal Stabilizer Into Routine Clinical Practice

NCT02562547

Cesarean Section Rate

COMPLETED

A Clinical Phase II Study of the Materna Device to Shorten Delivery Time During Childbirth

NCT06698185

Childbirth

WITHDRAWN NA

Evaluation of Maternal Feedback to Shorten Pushing Efforts During Labor

NCT02648867

Prolonged Second Stage of Labor

TERMINATED NA

Lower Limb Compression Prevents Hypotension After Epidural in Labor

NCT04750486

Labor Pain Maternal Hypotension

COMPLETED NA

Active Management Of Risk In Pregnancy At Term to Reduce Rate of Cesarean Deliveries

NCT00598260

Pregnancy

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Women may sometimes be reluctant to push resulting in a prolonged second stage labor, which could lead to a Cesarean section. This study will record the frequency of Cesarean sections in two groups to determine if there are any measurable differences.

The investigational device in this study is the HEM-AVERT® Perianal Stabilizer manufactured by Stetrix, Inc. This device has received previous FDA clearance as a Class II device to prevent hemorrhoids during childbirth. This study is being conducted by Stetrix, Inc. and falls within the guidelines set forth by the Food and Drug Administration in 21 CFR Section 812.2 as a non-significant risk study. The HEM-AVERT® Perianal Stabilizer is a Class II device in accordance with FDA regulation 21 CFR 890.5765. The Class II version of the device and the investigational device are identical in terms of materials, design, intended population and area used. The sole difference is that data will be collected in order to support an application to the FDA to obtain clearance of the device for the specific claim of reducing the C-section rate and/or reducing the second stage of labor times. This difference in data collection may be viewed as off-label use of the device although there is no new risk to the subject in the use of this device as an investigational device.

The primary objective of this study is to reduce the C-section rate and/or the second stage of labor times while using this device. For patients scheduled for a vaginal delivery, success is defined as completing the vaginal delivery process.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cesarean Section

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational

Application of the Hem-Avert device.

Group Type EXPERIMENTAL

Hem-Avert Perianal Stabilizer

Intervention Type DEVICE

Control

No Application of the Hem-Avert device.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hem-Avert Perianal Stabilizer

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pregnant women between the ages of 18 and 40 years old at the time of enrollment
2. Gestational age between 34 and 42 weeks at the time of enrollment
3. Live singleton gestation
4. Candidate for vaginal delivery.
5. Willing and able to comply with the study plan as indicated by understanding and signing the subject informed consent form

Exclusion Criteria

1. Subject unable to speak English
2. Subject unable to understand and sign the informed consent form
3. Delivery planned outside the clinical center
4. Subject is scheduled for vaginal delivery with anticipated complications (i.e. including but not limited to non-vertex presentation or macrosomia \>4,000 grams)
5. Subject scheduled for an elective cesarean birth
6. Preeclampsia with severe features, eclampsia, HELLP syndrome
7. Multiple Gestation
8. PROM (premature rupture of membranes)
9. Previous Cesarean Section
10. PTL (preterm labor)
11. Known major fetal anomaly or fetal demise.
12. Suspected or proven chorioamnionitis
13. Placenta previa
14. Maternal insulin dependent diabetes
15. Maternal health conditions deemed as risk factors by investigators such as renal or cardiopulmonary disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes